eXoZymes (EXOZ) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
eXoZymes (EXOZ) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 59.7% versus a loss of 62.1%. Kalaris Therapeutics is the larger company by market cap ($56.2 million vs $48.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | KLRS |
|---|---|---|
| Share price | $5.25 | $2.36 |
| Market cap | $48.85M | $56.18M |
| 1-day change | -1.50% | -5.60% |
| YTD return | -51.65% | -70.38% |
| 1-year return | -59.68% | -62.06% |
| 5-year return | — | -99.51% |
| EPS (TTM) | $-1.19 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.40 | $11.88 |
| 52-week low | $4.35 | $2.35 |
| Distance from 52-week high | -71.47% | -80.13% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +692.80% |
| Average volume | 6.97K | 252.88K |
| Shares outstanding | 9.30M | 23.80M |
| Employees | 32 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
EXOZ vs KLRS FAQ
Which is bigger, eXoZymes or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $56.18M compared with $48.85M for eXoZymes (EXOZ).
Which stock has performed better over the past year, EXOZ or KLRS?
EXOZ returned -59.68% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.